Ads
related to: enfortumab vedotin reviews- About PADCEV®
Discover How PADCEV® Treatment
May Work For You.
- PADCEV® Support Solutions
Access & Reimbursement Assistance
and Patient Coverage Support.
- How Is PADCEV Given
Learn About PADCEV® Administration
and View the Treatment Schedule.
- Tips For Caregivers
Learn How to Better Support Your
Loved One During Treatment .
- About PADCEV®
Search results
Results from the WOW.Com Content Network
Enfortumab vedotin, sold under the brand name Padcev, is an antibody-drug conjugate [6] used for the treatment of urothelial cancer. [4] [7] It is a nectin-4-directed antibody and microtubule inhibitor conjugate. [4] [7] Enfortumab refers to the monoclonal antibody part, and vedotin refers to the payload drug (MMAE) and the linker. [5]
The FDA accepts Seattle Genetics (SGEN) and Astellas' BLA for enfortumab vedotin under a priority review to treat advanced/metastatic urothelial cancer. A verdict is pending on Mar 15, 2020.
The European Medicines Agency accepts Seagen (SGEN) and Astellas Pharma's marketing application for enfortumab vedotin for treating adult patients with advanced/metastatic urothelial cancer.
In addition to brentuximab vedotin, Seattle Genetics' product pipeline includes enfortumab vedotin, being co-developed with Astellas Pharma, tisotumab vedotin, being co-developed with Genmab, SGN-LIV1A, an ADC targeting LIV-1, and several immuno-oncology agents in phase 1 studies.
In International Nonproprietary Names for MMAE-MAB-conjugates, the name vedotin refers to MMAE plus its linking structure to the antibody. [1] It is a potent antimitotic drug derived from peptides occurring in marine shell-less mollusc Dolabella auricularia called dolastatins which show potent activity in preclinical studies, both in vitro and ...
Tisotumab vedotin, sold under the brand name Tivdak, is an antibody-drug conjugate used to treat cervical cancer. [1] It is a combination of tisotumab, a monoclonal antibody against tissue factor , and monomethyl auristatin E (MMAE), a potent inhibitor of cell division .
Lifastuzumab vedotin: mab: humanized: phosphate-sodium co-transporter: cancer Ligelizumab [15] mab: humanized: IGHE: severe asthma, chronic spontaneous urticaria: Loncastuximab tesirine [87] [74] Zynlonta: mab: chimeric: CD19: Y: relapsed or refractory large B-cell lymphoma Losatuxizumab vedotin [28] mab: chimeric/ humanized: epidermal growth ...
Sacituzumab govitecan is indicated for the treatment of adults with metastatic triple-negative breast cancer who received at least two prior therapies for metastatic disease; [11] people with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease; [14] and for people ...
Ads
related to: enfortumab vedotin reviews